Zhang Y, Mayorga ME, Ivy J, Hassmiller Lich K, Swann JL. Modeling the impact of nonpharmaceutical interventions on COVID-19 transmission in K-12 schools. MDM Policy Pract. 2022 Dec 3;7(2):238146832. doi: 10.1177/23814683221140866
Wright S, Dalal G, Vass C, Georgsson S, Payne K. How do women want to receive information about non-invasive prenatal testing? Evidence from a discrete choice experiment. Prenat Diagn. 2022 Oct;42(11):1377-89. doi: 10.1002/pd.6243
Buchanan J, Hill M, Vass CM, Hammond J, Riedijk S, Klapwijk JE, Harding E, Lou S, Vogel I, Hui L, Ingvoldstad-Malmgren C, Soller MJ, Ormond KE, Choolani M, Zheng Q, Chitty LS, Lewis C. Factors that impact on women's decision-making around prenatal genomic tests: an international discrete choice survey. Prenat Diagn. 2022 Jun;42(7):934-46. doi: 10.1002/pd.6159
Sutphin J, DiSantostefano RL, Leach C, Hauber B, Mansfield C. Exploring decisional conflict with measures of numeracy and optimism in a stated preference survey. MDM Policy Pract. 2021 Nov 13;6(2):238146832. doi: 10.1177/23814683211058663
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Nguyen Thi Nhan P, Van Toan D, Que Huong T, Minh Nguyet D, Thanh Dao T, Minh Tri L, Khac Minh T, Hoc TP Y. 3D-pharmacophore modeling and its application on allosteric inhibitors of rac serin/threonin protein kinase AKT1. Journal of Ho Chi Minh City Pharmacy Association. 2018;22(S1):380-8.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. Untreated hypertension and the emergency department: a chance to intervene? Acad Emerg Med. 2008 Jun;15(6):529-36. doi: 10.1111/j.1553-2712.2008.00132.x
Umscheid CA, Maguire MG, Pines JM, Everett WW, Baren JM, Townsend RR, Mines D, Szyld D, Gross R. The prevalence of and risk factors associated with untreated hypertension in ED patients. Poster presented at the 2007 Society for Academic Emergency Medicine Conference; May 2007. Chicago, IL. [abstract] Acad Emerg Med. 2007; 14(5 Suppl 1):S117.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Ryan M, Diack J, Watson V, Smith N. Rapid prenatal diagnostic testing for down syndrome only or longer wait for full karyotype: the views of pregnant women. Prenat Diagn. 2005 Dec;25(13):1206-11. doi: 10.1002/pd.1309
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.